Issue Contents
|
|
Marketing Authorisations
|
|
|
|
|
No proven clinical advantages, either as an adjunct to or instead of hydroxycarbamide
|
|
|
|
|
|
|
|
|
|
Higher incidence of convulsive status epilepticus, and serious cardiovascular risks in the long term
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The complete contents of
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated.
